Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05939-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von JingCheng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China. Hauptthemen laut MEDLINE: Imatinib Mesylate, Cytidine Deaminase, Proto-Oncogene Proteins c-myc, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China.
- Department of Hematology, Lanxi People's Hospital, Lanxi, 321100, China.
- Department of Internal Medicine, Yongkang Traditional Chinese Medicine Hospital, Yongkang, 321000, China.
- Department of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, China. huhuixian@zju.edu.cn.
Zitieren
APA
Zhang, J., Zhou, S., Jiang, S., He, F., Tu, Y., & Hu, H. (2024). Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05939-4
Vancouver
Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H. Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05939-4
BibTeX
@article{Zhang2024,
author = {Zhang, JingCheng and Zhou, Sheng and Jiang, SiSi and He, Fang and Tu, Yan and Hu, HuiXian},
title = {Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05939-4}
}
EUVIMED